Gilead Sciences (GILD) Given a $94.00 Price Target at Mizuho

Mizuho set a $94.00 target price on Gilead Sciences (NASDAQ:GILD) in a research report released on Thursday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Evercore ISI reiterated a buy rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Raymond James decreased their price objective on shares of Gilead Sciences from $97.00 to $94.00 and set a strong-buy rating for the company in a report on Friday, October 26th. Barclays upped their price objective on shares of Gilead Sciences from $90.00 to $95.00 and gave the stock an overweight rating in a report on Friday, October 26th. Piper Jaffray Companies cut shares of Gilead Sciences from an overweight rating to a neutral rating and decreased their price objective for the stock from $85.00 to $75.00 in a report on Friday, October 26th. Finally, Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $87.00 to $88.00 and gave the stock an overweight rating in a report on Friday, October 26th. Thirteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $87.84.

Shares of NASDAQ:GILD opened at $69.44 on Thursday. The firm has a market capitalization of $90.02 billion, a P/E ratio of 8.11, a price-to-earnings-growth ratio of -2.69 and a beta of 1.01. Gilead Sciences has a 1 year low of $64.27 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.47 and a quick ratio of 3.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the prior year, the company posted $2.27 earnings per share. As a group, equities analysts anticipate that Gilead Sciences will post 6.44 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $239,408,146.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Reilly Financial Advisors LLC lifted its stake in shares of Gilead Sciences by 98.3% in the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Gilead Sciences in the second quarter valued at about $132,000. Brand Asset Management Group Inc. bought a new stake in shares of Gilead Sciences in the second quarter valued at about $139,000. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences in the third quarter valued at about $174,000. Finally, Wealthsource Partners LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at about $206,000. Institutional investors own 78.23% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: Understanding Market Liquidity

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply